Health & Environmental Research Online (HERO)


Print Feedback Export to File
7047259 
Journal Article 
Antileukemic activity of Flt3 ligand in murine leukemia 
Wang, A; Braun, SE; Sonpavde, G; Cornetta, K; , 
2000 
Yes 
Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445 
AMER ASSOC CANCER RESEARCH 
BIRMINGHAM 
1895-1900 
English 
10766177 
WOS:000086338000021 
Flt3-ligand (Flt3-L) is an early acting costimulatory cytokine that has been shown to possess antitumor properties in murine solid tumor models. Flt3-L is a hans-membrane protein (tm) but can be proteolytically cleaved to a soluble form, which is also biologically active. In this study, the antitumor effect of both soluble and tmFlt3-L was evaluated in a mouse leukemia model, To mimic the multiorgan involvement characteristic of human leukemia, a factor-dependent cell line FDC.91 was made leukemogenic by transfection with the human BCR/ABL gene. The resulting cell line, AW, expresses BCR/ABL RNA and protein. It maintains a similar in vitro growth rate as the parent cell line,but unlike the parent cell Line, AW cells are factor independent and tumorigenic, Growth of FDC.P1 and AW cells are unaffected by the addition of soluble human Flt3-L to the culture medium. Also, AW growth is unaltered after transduction with a retroviral vector expressing the tm isoform of human Flt3-L (AW/tmFlt3-L), When 10(5) AW cells were i.v. injected into syngeneic DBA/2 mice, fatal leukemia developed in nine of nine (100%) mice within 4-6 weeks with involvement of the blood, bone marrow, spleen, and thymus, Systematic administration of soluble human Flt3-L (500 mu g/kg/day) for 10 days protected mice from leukemia, with 11 of 17 mice tumor free at week 8 (64.7%) The hn isoform of Flt3-L also was protective. When 10(4) AW/tmFlt3-L cells were injected i.v. into mice, only 35.7% (5 of 14) developed leukemia versus 100% in control groups. Adoptive transfer of immunity was also demonstrated; T cells obtained from tumor-free animals conferred protection to 87% (seven of eight) naive mice challenged with AW cells. These results demonstrate that both soluble and membrane-bound human Flt3-L has antitumor activity in this leukemia model.